Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Academic Drug Discovery

Kamyar Hadian's Biography



Kamyar Hadian, Group Leader, Helmholtz Zentrum München

Dr. Kamyar Hadian is a Principal Investigator and the Head of the ‘Assay Development and Screening Platform’ at the Helmholtz Zentrum Muenchen in Munich/Germany. In parallel, he became an Adjunct Associate Research Scientist in the Department of Biological Sciences at the Columbia University (New York/USA) from 2016 till 2017.
His research focus is the identification and validation of novel molecular targets within ubiquitin signaling pathways and the subsequent development of strategies to interfere with these targets. He has in-depth experience in designing and running biochemical as well as cell-based assays for high-throughput and high-content screening in various disease areas such as cancer, immunology, virology, diabetes and more.
Kamyar studied Biology at the Technical University of Munich (TUM) and received his PhD from the Ludwig-Maximilians-University (LMU) in 2009 for his studies in HIV research, where he elucidated virus-host interactions. After a short post-doctoral period working in the field of NF-?B signaling, he was appointed the head of ‘Assay Development and Screening Platform’ at the Helmholtz Zentrum Muenchen in 2010. Five years later (in 2015), he received a tenure position.

Kamyar Hadian Image

Inhibition Of An E2/E3 Protein-Protein Interaction As A Novel Strategy To Counteract Autoimmune Diseases

Monday, 6 March 2017 at 17:00

Add to Calendar ▼2017-03-06 17:00:002017-03-06 18:00:00Europe/LondonInhibition Of An E2/E3 Protein-Protein Interaction As A Novel Strategy To Counteract Autoimmune DiseasesSELECTBIOenquiries@selectbiosciences.com

This presentation will give insights into the discovery of a novel E2/E3 protein-protein interaction small molecule inhibitor that we were able to validate and characterize in a variety of biochemical as well as cell-based assays including primary cell models. More importantly, we can show that this first-in-class inhibitor is highly effective in a pre-clinical autoimmune mouse model for Rheumatoid Arthritis.


Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonAcademic Drug DiscoverySELECTBIOenquiries@selectbiosciences.com